L773:1791 244X OR L773:1107 3756
Search: L773:1791 244X OR L773:1107 3756 > Labelling chemistry...
- 25 of 150
- Previous record
- Next record
- To hitlist
Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma
-
- Fortin, Marc-André (author)
- Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap
-
- Orlova, Anna (author)
- Uppsala universitet,Enheten för biomedicinsk strålningsvetenskap
-
- Malmström, Per-Uno (author)
- Uppsala universitet,Urologkirurgi
- show more...
- show less...
- (creator_code:org_t)
- 2007
- 2007
- English.
- In: International Journal of Molecular Medicine. - 1107-3756 .- 1791-244X. ; 19:2, s. 285-291
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- The direct instillation of radiolabelled conjugates in the urinary bladder is a promising path for the treatment of bladder carcinoma. The targeting of HER2/neu receptors expressed on the surface of many bladder carcinoma cells shows potential to be developed as a therapeutic strategy, and patients identified with a high risk of progression may benefit from adjuvant targeted radionuclide therapy. A phage-display selected Affibody molecule (Z(HER2:342)) which binds to HER2/neu with picomolar affinity, can be used for targeting HER2/neu-expressing bladder carcinomas. A DOTA-derivative of Z(HER2:342), designated as DOTA-Z(HER2:342)-3, is considered as a suitable targeting agent for therapy. The DOTA chelator provides stable labelling with radiometals, and the low molecular weight (7.2 kDa) of the DOTA-Z(HER2:342)-3 compound is expected to enable efficient tumor penetration. DOTA-Z(HER2:342)-3 was radiolabelled with 90Y and 177Lu in 1 M ammonium acetate buffer, at pH 5.5, and in the presence of ascorbic acid. Nearly quantitative labelling yields were achieved for both nuclides after 15 min of incubation at 60 degrees C. After chelation, the conjugates retained their capacity to specifically bind to HER2/neu-expressing SKOV-3 cells. The radiolabelled affibody conjugate (DOTA-Z(HER2:342)-3) demonstrated high antigen-binding capacity and good cellular retention. Biodistribution in normal mice demonstrated low uptake in all organs and tissues except for kidneys.
Keyword
- Animals
- Cell Line; Tumor
- Cell Survival/drug effects
- Humans
- Mice
- Recombinant Fusion Proteins/pharmacokinetics/*therapeutic use
- Urinary Bladder Neoplasms/*drug therapy/pathology
- Yttrium Radioisotopes/pharmacokinetics/*therapeutic use
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- International Journal of Molecular Medicine (Search for host publication in LIBRIS)
To the university's database
- 25 of 150
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Fortin, Marc-And ...
- Orlova, Anna
- Malmström, Per-U ...
- Tolmachev, Vladi ...
- Articles in the publication
- International Jo ...
- By the university
- Uppsala University
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
